Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
First patient dosed in Vial’s Phase Ib trial of IL-13 x TSLP antibody
Clinical-stage biotechnology company Vial has dosed the first patient in its Phase Ib clinical study evaluating interleukin-13 × thymic stromal …
-
AstraZeneca opens new R&D centre in Cambridge, US
AstraZeneca has opened a new global strategic research and development (R&D) facility in Massachusetts, US, as part of an investment …
-
First US commercial procedures completed with Emboline’s device
Emboline has reported the first commercial use of its Emboliner Embolic Protection System in the US during two procedures involving …
-
Genmab reports Phase I/II data for Rina-S in ovarian cancer
Genmab has reported data from Part C of the Phase I/II RAINFOL-01 trial of rinatabart sesutecan (Rina-S; GEN1184) in patients …
-
Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US
Bayer has announced plans to invest $2.2bn in a new pharmaceutical manufacturing facility in Ohio, US. The facility will be constructed …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Abbott rolls out SimpleScreen CRC blood test across US
Abbott has commercially rolled out SimpleScreen CRC in the US, introducing a blood test approved by the Food and Drug …
-
MSD’s Phase IIb study of tulisokibart achieves primary endpoint
Merck & Co (MSD) has reported that the Phase IIb MK-7240-012 study of its investigational humanised monoclonal antibody, tulisokibart, achieved …
-
BioMarin and Profluent partner on AI-designed enzyme therapies
BioMarin Pharmaceutical has entered a research collaboration with Profluent to design and optimise novel enzyme therapies for its drug development …
-
FDA clears Cepheid’s multiplex respiratory panel test
The US Food and Drug Administration (FDA) has granted clearance to Cepheid for its Xpert Respiratory Panel, a multiplex polymerase …
-
Lilly reports comparative data from ACHIEVE-3 and PIONEER PLUS studies
Eli Lilly and Company has reported findings from an indirect treatment comparison analysing data from the ACHIEVE-3 and PIONEER PLUS …
-
Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
Kyowa Kirin’s wholly owned subsidiary Kyowa Kirin International has signed an exclusive distribution agreement with Knight Therapeutics for Poteligeo (mogamulizumab) …
-
Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma
Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33, a clinical-stage anti-IL-33 monoclonal antibody, …
-
Patient enrolment concludes in Vasomune’s Phase IIa Pegevongitide trial
Vasomune Therapeutics has completed enrolment in its AV001-004 Phase IIa trial assessing Pegevongitide (AV-001) in patients hospitalised with pneumonia requiring …
-
Eden Radioisotopes gains support from New Mexico for $1.4bn medical facility
Eden Radioisotopes has secured support from the State of New Mexico for its planned $1.4bn medical isotope manufacturing facility in …
-
Daiichi Sankyo, MSD withdraw cancer drug application
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at …
